Loading...
•
Dec 31, 2020
Amphenol Q4 2020 Earnings Report
Amphenol's Q4 2020 earnings were reported, highlighted by record sales and EPS, driven by growth in mobile devices, industrial, and automotive markets, offset by declines in commercial aerospace and mobile networks.
Key Takeaways
Amphenol reported record fourth-quarter results with sales of $2.426 billion, up 13% year-over-year, and GAAP diluted EPS of $1.15, up 12% year-over-year. The company also announced a 2-for-1 stock split.
Record sales of $2.426 billion, up 13% in U.S. dollars and 11% organically compared to Q4 2019
Record GAAP diluted EPS of $1.15, up 12% compared to the prior year period
Record Adjusted Diluted EPS of $1.13, up 15% compared to the prior year period
Record operating and free cash flow of $441 million and $371 million, respectively
Amphenol
Amphenol
Forward Guidance
For the first quarter 2021, Amphenol expects sales to be in the range of $2.120 billion to $2.180 billion, representing 14% to 17% growth over 2020, and Adjusted Diluted EPS in the range of $0.90 to $0.94, representing 27% to 32% growth over 2020.
Positive Outlook
- Sales to be in the range of $2.120 billion to $2.180 billion
- Sales representing 14% to 17% growth over 2020
- Adjusted Diluted EPS in the range of $0.90 to $0.94
- Adjusted Diluted EPS representing 27% to 32% growth over 2020
- On a post-split basis, this would represent Adjusted Diluted EPS in the range of $0.45 to $0.47
Challenges Ahead
- Ongoing and significant economic and public health uncertainties created by the COVID-19 pandemic make it difficult to accurately forecast the Company’s performance for the full year 2021.
- Not providing full-year sales and EPS guidance at this time.
- New material disruptions from the pandemic
- Assuming constant exchange rates
- The extent to which the COVID-19 pandemic will continue to impact our business and financial results going forward will be dependent on future developments such as the length and severity of the crisis, future government regulations and actions in response to the crisis, the timing, effectiveness and availability of vaccines